Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TTY Biopharm CoROCO:4105 -0.76%85 5-Year Yield-on-Cost % is 5.71 as of Aug. 23, 2026, which is 8% above its 10-year median of 5.30. GuruFocus rates ROCO:4105 with a GF Score™ of 85/100 and a GF Value™ of NT$87.48 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 507 Drug Manufacturers companies, TTY Biopharm Co ranks better than 75.94% on this metric.
TTY Biopharm Co's yield on cost for the quarter that ended in Jun. 2026 was 5.71.
The historical rank and industry rank for TTY Biopharm Co's 5-Year Yield-on-Cost % or its related term are showing as below:
ROCO:4105'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.61 Med: 5.3 Max: 9.8
Current: 5.71
During the past 13 years, TTY Biopharm Co's highest Yield on Cost was 9.80. The lowest was 2.61. And the median was 5.30.
ROCO:4105's 5-Year Yield-on-Cost % is ranked better than 75.94% of 507
companies
in the Drug Manufacturers industry
Industry Median: 2.36
vs ROCO:4105: 5.71
TTY Biopharm Co (ROCO:4105) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
TTY Biopharm Co 5-Year Yield-on-Cost % Related Terms
ROCO:4105 vs ZTS: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, TTY Biopharm Co's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TTY Biopharm Co 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, TTY Biopharm Co's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where TTY Biopharm Co's 5-Year Yield-on-Cost % falls into.
TTY Biopharm Co 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of TTY Biopharm Co is calculated as
TTY Biopharm Co (ROCO:4105) has a 5-Year Yield-on-Cost % of 5.71 as of Aug. 23, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on TTY Biopharm Co and its competitors. This is near median its historical median of 5.30. Over the past decade, TTY Biopharm Co's 5-Year Yield-on-Cost % has ranged from 2.61 to 9.80. According to the industry distribution chart, TTY Biopharm Co ranks #122 out of 507 companies in the Drug Manufacturers industry, placing it in the top 24.1%.
Is TTY Biopharm Co's 5-Year Yield-on-Cost % too high?
TTY Biopharm Co's current 5-Year Yield-on-Cost % of 5.71 is near median its 10-year median of 5.30. Over the past 10 years, this metric has ranged from a low of 2.61 to a high of 9.80. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.36. TTY Biopharm Co's value of 5.71 is 141.9% above this industry median. Based on the distribution chart, TTY Biopharm Co ranks #122 out of 507 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, TTY Biopharm Co has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TTY Biopharm Co's 5-Year Yield-on-Cost % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, TTY Biopharm Co ranks #122 out of 507 companies for 5-Year Yield-on-Cost %. This places TTY Biopharm Co in the top 24% of its industry — outperforming the majority of peers. The industry median 5-Year Yield-on-Cost % is 2.36. TTY Biopharm Co's value of 5.71 is 141.9% above this benchmark. Historically, TTY Biopharm Co's own 5-Year Yield-on-Cost % has ranged from 2.61 to 9.80 over the past decade. While the company's 10-year median is 5.30 vs. the industry median of 2.36, TTY Biopharm Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.36, based on 507 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TTY Biopharm Co's current 5-Year Yield-on-Cost % of 5.71 is 141.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on TTY Biopharm Co and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TTY Biopharm Co's current 5-Year Yield-on-Cost % is 5.71, which is near median its own 10-year median of 5.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TTY Biopharm Co stock overvalued right now?
Based on GuruFocus' analysis, TTY Biopharm Co (ROCO:4105) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$87.48, compared to a current price of NT$78.40 — trading 10.4% below its estimated fair value. The current 5-Year Yield-on-Cost % is 5.71, which is near median its 10-year median of 5.30 and 141.9% above the Drug Manufacturers industry median of 2.36. TTY Biopharm Co's overall GF Score™ is 85/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For TTY Biopharm Co (ROCO:4105), the current 5-Year Yield-on-Cost % is 5.71 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TTY Biopharm Co (ROCO:4105) Overvalued in 2026?
Based on GuruFocus' analysis, TTY Biopharm Co stock appears to be undervalued.
The current stock price of NT$78.40 is trading 10.4% below its estimated GF Value™ of NT$87.48.
GuruFocus considers TTY Biopharm Co to be Modestly Undervalued.
Key valuation signals for ROCO:4105:
5-Year Yield-on-Cost %: 5.71 (near median its 10-year median of 5.30)
GF Value™: NT$87.48 vs. price of NT$78.40 (10.4% below fair value)
Industry Position: 141.9% above the Drug Manufacturers median (#122 of 507)
No single metric tells the full story. See the ROCO:4105 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TTY Biopharm Co Ltd is engaged in the manufacturing and marketing of pharmaceuticals and chemical drugs. The company's operating segments includes Oncology Business unit, Health Care Business unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business unit segment. It generates maximum revenue from the Oncology segment. Geographically, it derives a majority of revenue from Taiwan and also has a presence in America. Some of its products include Algitab, Alginos, Sulfin, Metacin, Cepiro, Brosym, Colimycin, Cubicin, and others.
85GF Score
Get the complete analysis for ROCO:4105
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4105 has been successfully added to your 
